$STE

Carestio Daniel A sold $947K of STE

Carestio Daniel A (President and CEO) sold 4,428 shares of STERIS plc (STE) at an average of $213.82 ($212.00–$214.64, $0.95M total) across 2 trades over 2026-06-04 to 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Carestio Daniel A
Published Jun 8, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The only new information is the CEO’s open-market sale details (size, price range, and 10b5-1 pre-arrangement).

02

Market read

Traders may monitor for follow-on scheduled insider activity, but the 10b5-1 designation limits interpretive value for fundamentals.

03

What to watch

The article doesn’t state whether the CEO’s remaining holdings are subject to other scheduled sales, nor does it provide context on option exercises/compensation—those could offset the net selling narrative.

Relevance 4/10Novelty 5/10Timing: Filed June 8, covering sales executed June 4–5

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for STERIS plc (STE).

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

SEC Form 4 shows STE CEO sold 4,428 shares in open-market transactions totaling about $946.8K under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

Minimal—this is company-specific insider activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with valuation or liquidity needs; traders may treat it as a mild overhang if price is extended.

Key entities

  • STERIS plc

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • Carestio Daniel A

    President and CEO who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

$STEHighAI 9/10

Steris Announces Major Acquisition of Xodus Medical, Inc.

STERIS (STE) agreed to acquire Xodus Medical, Inc. for $2.1B in cash, with up to $150M in earnout payments, subject to regulatory approval. The deal is expected to close by December 31, 2026, and will be financed primarily with debt. Analysts rate STE stock as Buy with a $269 price target, citing strong financial quality and growth guidance.

$STEHighAI 9/10

Steris inks $2.1B Xodus buyout to expand consumables portfolio

Steris (STE) agreed to acquire Xodus Medical for $2.1B, expecting $245M in annual sales. The deal expands Steris' healthcare consumables portfolio, with debt financing and potential performance-based payouts. Analysts expect earnings per share growth from 2027. Steris aims to close the deal this year, following its M&A strategy focused on hospital-related technology.

$STEHighAI 9/10

Steris outlays $2.1bn to acquire Xodus Medical

Steris (STE) agreed to acquire Xodus Medical, a privately held surgical safety solutions developer, for $2.1 billion. The deal will expand Steris's healthcare consumables portfolio, including Xodus's surgical products like the Pink Pad. Steris expects the acquisition to complement its offerings and drive growth, with Xodus projecting $245 million in 2026 revenue. Steris's healthcare consumables segment grew 10% year-on-year in Q2 2026.